BUSINESS
Takeda/TiGenix Cell Therapy for Crohn’s Disease Complication Gets European Panel Nod
Takeda Pharmaceutical and Belgium biotech TiGenix said on December 15 that their stem cell therapy Cx601 (darvadstrocel) has earned the green light of a key European panel for treating complex perianal fistulas in Crohn’s disease. The European Medicines Agency’s (EMA)…
To read the full story
Related Article
- Stem Cell Therapy Alofisel Wins European Approval: Takeda
March 27, 2018
BUSINESS
- Sumitomo to Launch Post-Marketing Study for iPSC Therapy by Year-End
March 9, 2026
- Drug Pricing Reform Draws Sharp Industry Backlash in Jiho Poll
March 9, 2026
- Nitrosamine Detected in Nichi-Iko’s Tryptanol, No Need to Halt Prescriptions
March 9, 2026
- Pfizer, ASKA to Co-Promote RSV Vaccine Abrysvo in Japan
March 9, 2026
- Towa Broadens Label for Tacrolimus in Cell Transplantation
March 9, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





